■T-DXd
Phase 1
(US/EU/Asia) HER2+ BC 2L+/1L
DESTINY-Breast07
(US/EU/Asia) HER2 low BC
Chemo naïve/post chemo
DESTINY-Breast08
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L
DESTINY-Gastric03
(US/EU/Asia) HER2+ NSCLC
(durvalumab, volrustomig combo) 1L
DESTINY-Lung03
(US/EU) BC, NSCLC
(pembrolizumab combo)
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(US/EU/Asia) solid tumors
(saruparib combo)
PETRA
Phase 2
(CN) HER2 expressing solid tumors
DESTINY-PanTumor03
Phase 3
(JP/US/EU/Asia) HER2+ BC
adjuvant*1
DESTINY-Breast05
(JP/US/EU/Asia) HER2 low BC
chemo naïve
DESTINY-Breast06
(JP/US/EU/Asia) HER2+ BC 1L
DESTINY-Breast09
(JP/US/EU/Asia) HER2+ BC
neoadjuvant
DESTINY-Breast11
(JP/EU/Asia) HER2+ GC 2L
DESTINY-Gastric04
(JP/US/EU/Asia) NSCLC
(w/ HER2 exon 19 or exon 20 mutation) 1L
DESTINY-Lung04
Regulatory Phase
(CN) HER2+ GC 3L
DESTINY-Gastric06
(CN) HER2 mutant NSCLC 2L+
DESTINY-Lung05
|
Breakthrough Designation (US) |
*1 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small celllung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer, ESCC: esophageal squamous cell carcinoma
■Dato-DXd
Phase 1
(JP/US) solid tumors
TROPION-PanTumor01
(CN) NSCLC, TNBC
TROPION-PanTumor02
(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo)
TROPION-Lung02
(JP/US/EU) NSCLC (w/o AGA, durvalumab, rilvegostomig, volrustomig, and sabestomig combo) TROPION-Lung04
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) solid tumors
(saruparib combo)
PETRA
Phase 2
(JP/US/EU/Asia) solid tumors
TROPION-PanTumor03
(JP/US/EU/Asia) EGFR mutated
NSCLC (osimertinib combo) 2L
ORCHARD
(US/EU/Asia) resectable early-stage NSCLC (durvalumab combo) neoadjuvant
NeoCOAST-2
Phase 3
(JP/US/EU/Asia) non-squamous NSCLC (w/o AGA, pembrolizumab combo) 1L
TROPION-Lung07
(JP/US/EU/Asia) NSCLC (w/o AGA, pembrolizumab combo) 1L
TROPION-Lung08
(JP/US/EU/Asia) in prep PD-L1 high nonsquamous NSCLC (w/o AGA, rilvegostomig combo) 1L
TROPION-Lung10
(JP/US/EU/Asia) in prep EGFR mutated NSCLC (osimertinib combo) 1L
TROPION-Lung14
(JP/US/EU/Asia) TNBC (PD-1/PD-L1 inhibitor ineligible) 1L
TROPION-Breast02
(JP/US/EU/Asia) TNBC
adjuvant*2 (mono or durvalumab combo)
TROPION-Breast03
(JP/US/EU/Asia) TNBC neoadjuvant and adjuvant (durvalumab combo)
TROPION-Breast04
(JP/US/EU/Asia) PD-L1 positive TNBC 1L (mono or durvalumab combo)
TROPION-Breast05
Regulatory Phase
(US/EU) NSCLC 2/3L
TROPION-Lung01
(JP/US/EU/Asia) BC*3 2/3L
TROPION-Breast01
*2 Adjuvant therapy for TNBC patients withresidual invasive disease following neoadjuvant therapy
*3 HR+, HER2 low or negative BC
BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small celllung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer
■HER3-DXd ■DS-7300 (I-DXd) ■DS-6000 (R-DXd)
Phase 1
(JP/US/EU/Asia) NSCLC
(JP/US/Asia) EGFR mutated NSCLC, 1/2L
(osimertinib combo)
(JP/US)
ESCC, CRPC, squamous NSCLC, SCLC, etc.
IDeate-PanTumor01
(JP/US/EU/Asia) in prep
ES-SCLC, 1L
IDeate-PanTumor03
(JP/US)
Renal cell carcinoma, ovarian cancer
Phase 2
(JP/US/EU/Asia)
melanoma SCCHN, HER2 negative GC, 2L+
HERTHENA-PanTumor01
(JP/US/EU/Asia)
ES-SCLC, 2L
IDeate-Lung01
(JP/US/EU/Asia)
solid tumors, 2L+
(JP/US/EU/Asia)
ovarian cancer
REJOICE-Ovarian01
Phase 3
(JP/US/EU/Asia)
EGFR mutated NSCLC 2L
HERTHENA-Lung02
(JP/US/EU/Asia) in prep
ES-SCLC, 2L+
IDeate-Lung02
Regulatory Phase
(US)
EGFR mutated NSCLC 3L
HERTHENA-Lung01
|
Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
|
|
|
Breakthrough Designation (US) |
|
Orphan drug designation (designated in at least one country/region among JP, US and EU |
BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small celllung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer